REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Net Income (Loss) Attributable to Parent USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Reviva Pharmaceuticals Holdings, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2024.
  • Reviva Pharmaceuticals Holdings, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$7.43 M, a 8.49% decline year-over-year.
  • Reviva Pharmaceuticals Holdings, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$39.8 M, a 43.6% decline year-over-year.
  • Reviva Pharmaceuticals Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$39.3 M, a 38.9% decline from 2022.
  • Reviva Pharmaceuticals Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$28.3 M, a 232% decline from 2021.
  • Reviva Pharmaceuticals Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$8.52 M, a 125% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$39.8 M -$7.43 M -$582 K -8.49% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$39.3 M -$9.36 M +$750 K +7.42% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-15
Q3 2023 -$40 M -$11.3 M -$5.9 M -108% Jul 1, 2023 Sep 30, 2023 10-K 2024-04-15
Q2 2023 -$34.1 M -$11.7 M -$6.37 M -119% Apr 1, 2023 Jun 30, 2023 10-K 2024-04-15
Q1 2023 -$27.7 M -$6.85 M +$513 K +6.97% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$28.3 M -$10.1 M -$6.42 M -174% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 -$21.8 M -$5.45 M -$3.17 M -139% Jul 1, 2022 Sep 30, 2022 10-K 2024-04-15
Q2 2022 -$18.7 M -$5.34 M -$3.73 M -232% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$14.9 M -$7.37 M -$6.42 M -676% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$8.52 M -$3.68 M -$3.34 M -958% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$5.19 M -$2.28 M -$1.62 M -246% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$3.57 M -$1.61 M -$757 K -88.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$2.81 M -$949 K -$200 K -26.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$2.61 M -$348 K -$485 K -355% Sep 1, 2020 Nov 30, 2020 10-Q 2021-01-14
Q3 2020 -$2.12 M -$659 K -$933 K -340% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$1.19 M -$851 K -$1.19 M -352% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $592 -$749 K -$1.06 M -344% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $1.06 M $137 K -$126 K -48% Sep 1, 2019 Nov 30, 2019 10-Q 2021-01-14
Q3 2019 $1.18 M $274 K +$257 K +1451% Jun 1, 2019 Aug 31, 2019 10-Q 2021-01-14
Q2 2019 $926 K $338 K +$352 K Mar 1, 2019 May 31, 2019 10-Q 2021-01-14
Q1 2019 $574 K $307 K Dec 1, 2018 Feb 28, 2019 10-K 2020-05-04
Q4 2018 $263 K Sep 1, 2018 Nov 30, 2018 10-Q 2020-01-10
Q3 2018 $17.7 K Jun 1, 2018 Aug 31, 2018 10-Q 2020-01-10
Q2 2018 -$13.3 K Mar 20, 2018 May 31, 2018 10-Q 2020-01-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.